VIRIDIAN THERAPEUTICS INC

Insider buying at Viridian signals bullish confidence after FDA approval of its TED therapy, boosting long‑term investor outlook.

Fairmount’s $17 buy of 1.18 M Viridian shares after the $117 M equity round signals strong confidence in the biotech’s TED pipeline and growth strategy.